- Home
- KPTI vs IAF Comparison
KPTI vs IAF Comparison
Compare KPTI & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- IAF
- Stock Information
- Founded
- KPTI 2008
- IAF 1985
- Country
- KPTI United States
- IAF United States
- Employees
- KPTI N/A
- IAF N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- IAF Finance/Investors Services
- Sector
- KPTI Health Care
- IAF Finance
- Exchange
- KPTI Nasdaq
- IAF Nasdaq
- Market Cap
- KPTI 103.5M
- IAF 115.5M
- IPO Year
- KPTI 2013
- IAF N/A
- Fundamental
- Price
- KPTI $0.64
- IAF $4.18
- Analyst Decision
- KPTI Strong Buy
- IAF
- Analyst Count
- KPTI 4
- IAF 0
- Target Price
- KPTI $5.00
- IAF N/A
- AVG Volume (30 Days)
- KPTI 1.0M
- IAF 90.4K
- Earning Date
- KPTI 11-05-2024
- IAF 01-01-0001
- Dividend Yield
- KPTI N/A
- IAF 11.44%
- EPS Growth
- KPTI N/A
- IAF N/A
- EPS
- KPTI N/A
- IAF N/A
- Revenue
- KPTI $148,442,000.00
- IAF N/A
- Revenue This Year
- KPTI $6.67
- IAF N/A
- Revenue Next Year
- KPTI $8.58
- IAF N/A
- P/E Ratio
- KPTI N/A
- IAF N/A
- Revenue Growth
- KPTI 1.77
- IAF N/A
- 52 Week Low
- KPTI $0.63
- IAF $3.60
- 52 Week High
- KPTI $1.95
- IAF $4.59
- Technical
- Relative Strength Index (RSI)
- KPTI 25.28
- IAF 27.16
- Support Level
- KPTI $0.75
- IAF $4.30
- Resistance Level
- KPTI $0.83
- IAF $4.39
- Average True Range (ATR)
- KPTI 0.05
- IAF 0.07
- MACD
- KPTI -0.01
- IAF -0.03
- Stochastic Oscillator
- KPTI 4.21
- IAF 24.51
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.